<ion-header>
    <ion-navbar color="primary">
        <ion-title>Antimicrobials Guidelines</ion-title>
    </ion-navbar>
</ion-header>


<ion-content no-bounce>
    <ion-list>
        <ion-item tappable (click)="guideLineContent1()">
            Initiating Colistin
        </ion-item>
        <ion-item tappable (click)="guideLineContent2()">
            To protect the Carbapenems and Linezolid from overuse
        </ion-item>
        <ion-item tappable (click)="guideLineContent3()">
            De-escalation / Escalation
        </ion-item>
        <ion-item tappable (click)="guideLineContent4()">
            Indications for Carbapenem use
        </ion-item>
        <ion-item tappable (click)="guideLineContent5()">
            Reference
        </ion-item>
    </ion-list>

    <br>
    
    <ion-card #guideline1 padding-top>
        <ion-card-header color="primary" text-wrap>
            The following criteria has been proposed for initiating Colistin
        </ion-card-header>
        <ion-card-content>
            <ul [ngStyle]="{'list-style-type': 'none', 'padding-left': '0px'}">
                <li text-wrap>
                    1. Pan-resistant organism as per culture report with evidence of invasive disease-fever/leuococytosis/ elevated Procalcitonin (PCT) or culture from a sterile site
                </li>
                <br>
                <li>2. Clinical failure of all other classes of antibiotics over 72 hours
                </li><br>
                <li>
                    3. Colistin to be given with loading does in combination with beta lactum class of antibiotics
                </li>
            </ul>
            <ion-buttons end>
                <button ion-button icon-end color="danger" clear (click)="scrollToTop()">
                    Scroll To Top
                    <ion-icon name="arrow-round-up">

                    </ion-icon>
                </button>
            </ion-buttons>
        </ion-card-content>
    </ion-card>

    <ion-card #guideline2 padding-top>
        <ion-card-header color="primary" text-wrap>
            The following criteria has been proposed to protect the Carbapenems and Linezolid from overuse
        </ion-card-header>
        <ion-card-content>
            <ul [ngStyle]="{'list-style-type': 'none', 'padding-left': '0px'}">
                <li>
                    1.Severe sepsis as defined by more than one organ failure of new onset and / or elevated serum lactate
                </li>
                <br>
                <li>2.Clinical failure of other classes of antibiotics over 48 hours in terms of worsening inflammatory markers, unresolving fever and new / worsening hemodynamic instability
                </li><br>
                <li>
                    3.Underlying severe immuno - supperssion - Neutropenea, immuno-suppressive therapy,Diabetic ketoacidosis (DKA) etc
                </li><br>
                <li> 4.The organism is susceptible to only carbapenems/linezolid,as per culture report
                </li>
            </ul>
            <ion-buttons end>
                <button ion-button icon-end color="danger" clear (click)="scrollToTop()">
                    Scroll To Top
                    <ion-icon name="arrow-round-up">

                    </ion-icon>
                </button>
            </ion-buttons>
        </ion-card-content>
    </ion-card>

    <ion-card #guideline3 padding-top>
        <ion-card-header color="primary" text-wrap>
            Some guiding principles for de-escalation/Escalation:
        </ion-card-header>
        <ion-card-content>
            <ul [ngStyle]="{'list-style-type': 'none', 'padding-left': '0px'}">
                <li text-justify>
                    1.If ESBL +ve:drug choice is monotheraphy with carbepenems. Preferably choose group I carbepenem. Piperacillin-Tazobactum and Cefoperazone-Sulbactum can be used if in-vitro sensitive and for mild infections
                </li>
                <br>
                <li>2.Vancomycin should be used only for confirmed MRSA infections and not in MSSA infections
                </li><br>
                <li>
                    3.In case of Pan drug resistant Pseudomonas / Acinetobacter spp. Combination therapy uisng colistin along with beta-lactams (using PK/PD principles)should be discussed with microbiologist /physician
                </li>
            </ul>
            <ion-buttons end>
                <button ion-button icon-end color="danger" clear (click)="scrollToTop()">
                    Scroll To Top
                    <ion-icon name="arrow-round-up">

                    </ion-icon>
                </button>
            </ion-buttons>
        </ion-card-content>
    </ion-card>

    <ion-card #guideline4 padding-top>
        <ion-card-header color="primary" text-wrap>
            Indications for Carbapenem use:
        </ion-card-header>
        <ion-card-content>
                <ul [ngStyle]="{'list-style-type': 'none', 'padding-left': '0px'}">
                    <li text-wrap>
                        1. Infections (e.g., bacteremia, pyelonephritis, intra-abdominal infections , peritonitis, cholangitis, abscesses), nosocomia Pnneumonia etc.) confirmed (by appropriate culture and susceptibility studies) to be caused by Gram-negative bacteria (E coli,
                        Klebsiella spp., Enterobacter spp.,Pseudomonas aeruginosa, other non-fermenting Gram-negative bacilli) resistant to other classes of antimicrobials and susceptible only to carbapenems in-vitro
                    </li>
                    <br>
                    <li>2. Initial empiric treatment for severe, life-threatening infections (associated with multi-organ dysfunction, septic shock) caused by Gram-negative bacteria.
                    </li><br>
                    <li>
                        *Febrile neutropenia
                    </li><br>
                    <li>*ventilator associated / nosocomial pneumonia
                    </li>
                    <br>
                    <li>
                        *Pyelonephritis / complicated urinary tract infections
                    </li><br>
                    <li>*Complicated intra - abdominal infections
                    </li>
                    <br>
                    <li>
                        Once the culture and susceptibility reports are available,choose the most appropriate antibiotic based on spectrum of activity, toxicity and cost (de-escalation)
                    </li>
                </ul>
            <ion-buttons end>
                <button ion-button icon-end color="danger" clear (click)="scrollToTop()">
                    Scroll To Top
                    <ion-icon name="arrow-round-up">

                    </ion-icon>
                </button>
            </ion-buttons>
        </ion-card-content>
    </ion-card>

    <ion-card #guideline5 padding-top>
        <ion-card-header color="primary" text-wrap>
            Reference:
        </ion-card-header>
        <ion-card-content>
            <ol [ngStyle]="{'list-style-type': 'none', 'padding-left': '0px'}">
                <li text-justify>
                    National Treatment Guidelines for Antimicrobial.
                </li>
                <br>
                <li>Ministry in infectious Diseases (2016).
                </li><br>
                <li>
                    Ministry of Health & Family Welfare Government of india.
                </li>
            </ol>
            <ion-buttons end>
                <button ion-button icon-end color="danger" clear (click)="scrollToTop()">
                    Scroll To Top
                    <ion-icon name="arrow-round-up">

                    </ion-icon>
                </button>
            </ion-buttons>
        </ion-card-content>
    </ion-card>

</ion-content>